- Home
- RPD vs HRMY Comparison
RPD vs HRMY Comparison
Compare RPD & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- HRMY
- Stock Information
- Founded
- RPD 2000
- HRMY 2017
- Country
- RPD United States
- HRMY United States
- Employees
- RPD N/A
- HRMY N/A
- Industry
- RPD Computer Software: Prepackaged Software
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- RPD Technology
- HRMY Health Care
- Exchange
- RPD Nasdaq
- HRMY Nasdaq
- Market Cap
- RPD 1.5B
- HRMY 1.8B
- IPO Year
- RPD 2015
- HRMY 2020
- Fundamental
- Price
- RPD $23.40
- HRMY $34.00
- Analyst Decision
- RPD Hold
- HRMY Strong Buy
- Analyst Count
- RPD 19
- HRMY 9
- Target Price
- RPD $32.94
- HRMY $54.44
- AVG Volume (30 Days)
- RPD 872.3K
- HRMY 642.5K
- Earning Date
- RPD 08-07-2025
- HRMY 08-05-2025
- Dividend Yield
- RPD N/A
- HRMY N/A
- EPS Growth
- RPD N/A
- HRMY 13.13
- EPS
- RPD 0.41
- HRMY 2.62
- Revenue
- RPD $849,159,000.00
- HRMY $744,852,000.00
- Revenue This Year
- RPD $2.81
- HRMY $20.10
- Revenue Next Year
- RPD $4.05
- HRMY $18.01
- P/E Ratio
- RPD $56.57
- HRMY $13.10
- Revenue Growth
- RPD 6.19
- HRMY 20.62
- 52 Week Low
- RPD $21.61
- HRMY $26.47
- 52 Week High
- RPD $44.48
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- RPD 46.92
- HRMY 58.91
- Support Level
- RPD $23.83
- HRMY $31.70
- Resistance Level
- RPD $25.85
- HRMY $35.08
- Average True Range (ATR)
- RPD 0.90
- HRMY 0.95
- MACD
- RPD 0.08
- HRMY 0.27
- Stochastic Oscillator
- RPD 25.53
- HRMY 71.80
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.